ProfileGDS5678 / 1433317_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 30% 32% 32% 32% 33% 31% 31% 31% 32% 32% 32% 31% 32% 32% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7116830
GSM967853U87-EV human glioblastoma xenograft - Control 22.7224632
GSM967854U87-EV human glioblastoma xenograft - Control 32.7224732
GSM967855U87-EV human glioblastoma xenograft - Control 42.6666732
GSM967856U87-EV human glioblastoma xenograft - Control 52.7015333
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7895431
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7506431
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7000531
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7060832
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7063332
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7105632
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6784831
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7177832
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.711932